AGL Quote, Financials, Valuation and Earnings

InnovAge Holding has a net margin of -8.11% compared to Agilon Health's net margin of -2.4%. Agilon Health's return on equity of -55.42% beat InnovAge Holding's return on equity of -5.29%.

Agilon Health has a consensus price target of $2.86, signalling upside risk potential of 45.42%. On the other hand InnovAge Holding has an analysts' consensus of $5.50 which suggests that it could grow by 31.27%. Given that Agilon Health has higher upside potential than InnovAge Holding, analysts believe Agilon Health is more attractive than InnovAge Holding.

Agilon Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InnovAge Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Agilon Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InnovAge Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilon Health pays -- of its earnings as a dividend. InnovAge Holding pays out -- of its earnings as a dividend.

Agilon Health quarterly revenues are $1.5B, which are larger than InnovAge Holding quarterly revenues of $205.1M. Agilon Health's net income of -$117.6M is lower than InnovAge Holding's net income of -$4.9M. Notably, Agilon Health's price-to-earnings ratio is -- while InnovAge Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilon Health is 0.14x versus 0.72x for InnovAge Holding. Usually stocks with elevated PS ratios are considered overvalued.

National Healthcare has a net margin of -8.11% compared to Agilon Health's net margin of 12.58%. Agilon Health's return on equity of -55.42% beat National Healthcare's return on equity of 13.34%.

Agilon Health has a consensus price target of $2.86, signalling upside risk potential of 45.42%. On the other hand National Healthcare has an analysts' consensus of -- which suggests that it could fall by --. Given that Agilon Health has higher upside potential than National Healthcare, analysts believe Agilon Health is more attractive than National Healthcare.

Agilon Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Healthcare has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.321%.

Agilon Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Healthcare offers a yield of 2.15% to investors and pays a quarterly dividend of $0.61 per share. Agilon Health pays -- of its earnings as a dividend. National Healthcare pays out 53.24% of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilon Health quarterly revenues are $1.5B, which are larger than National Healthcare quarterly revenues of $340.2M. Agilon Health's net income of -$117.6M is lower than National Healthcare's net income of $42.8M. Notably, Agilon Health's price-to-earnings ratio is -- while National Healthcare's PE ratio is 14.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilon Health is 0.14x versus 1.42x for National Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Sonida Senior Living has a net margin of -8.11% compared to Agilon Health's net margin of -18.41%. Agilon Health's return on equity of -55.42% beat Sonida Senior Living's return on equity of -145.3%.

Agilon Health has a consensus price target of $2.86, signalling upside risk potential of 45.42%. On the other hand Sonida Senior Living has an analysts' consensus of -- which suggests that it could grow by 5.49%. Given that Agilon Health has higher upside potential than Sonida Senior Living, analysts believe Agilon Health is more attractive than Sonida Senior Living.

Agilon Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sonida Senior Living has a beta of 1.798, suggesting its more volatile than the S&P 500 by 79.772%.

Agilon Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonida Senior Living offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilon Health pays -- of its earnings as a dividend. Sonida Senior Living pays out -- of its earnings as a dividend.

Agilon Health quarterly revenues are $1.5B, which are larger than Sonida Senior Living quarterly revenues of $74.8M. Agilon Health's net income of -$117.6M is lower than Sonida Senior Living's net income of -$13.8M. Notably, Agilon Health's price-to-earnings ratio is -- while Sonida Senior Living's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilon Health is 0.14x versus 0.99x for Sonida Senior Living. Usually stocks with elevated PS ratios are considered overvalued.

10x Genomics has a net margin of -8.11% compared to Agilon Health's net margin of -23.58%. Agilon Health's return on equity of -55.42% beat 10x Genomics's return on equity of -24.99%.

Agilon Health has a consensus price target of $2.86, signalling upside risk potential of 45.42%. On the other hand 10x Genomics has an analysts' consensus of $20.29 which suggests that it could grow by 44.49%. Given that Agilon Health has higher upside potential than 10x Genomics, analysts believe Agilon Health is more attractive than 10x Genomics.

Agilon Health has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison 10x Genomics has a beta of 1.839, suggesting its more volatile than the S&P 500 by 83.931%.

Agilon Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 10x Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilon Health pays -- of its earnings as a dividend. 10x Genomics pays out -- of its earnings as a dividend.

Agilon Health quarterly revenues are $1.5B, which are larger than 10x Genomics quarterly revenues of $151.7M. Agilon Health's net income of -$117.6M is lower than 10x Genomics's net income of -$35.8M. Notably, Agilon Health's price-to-earnings ratio is -- while 10x Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilon Health is 0.14x versus 2.67x for 10x Genomics. Usually stocks with elevated PS ratios are considered overvalued.